Metabolic and Bio-behavioral Effects of Following Recommendations in the Dietary Guidelines for Americans

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexFemale
Age19-64
SponsorUSDA, Western Human Nutrition Research Center

About this trial

This study, at the Western Human Nutrition Research Center (WHNRC), will focus on whether or not achieving and maintaining a healthy body weight is the most important health promoting recommendation of the Dietary Guidelines for Americans (DGA).The investigators hypothesize that improvement in cardiometabolic risk factors resulting from eating a DGA style diet will be greater in people whose energy intake is restricted to result in weight loss compared to those who maintain their weight. The investigators further propose that during a state of energy restriction, a higher nutrient quality diet such as the DGA style diet pattern, will result in greater improvement in cardiometabolic risk factors compared to a typical American diet (TAD) pattern that tends to be lower nutrient quality (more energy-dense and less nutrient-rich.)

Eligibility criteria

Qualifiers

Body Mass Index (BMI) 23-39.9 kg/m2 or 32-50% body fat percentage

Willingness to have blood drawn

The criteria listed above and at least one of the following: Fasting glucose ≥100 mg/dL but <126 mg/dL or Fasting triglyceride ≥125 mg/dL or HDL-cholesterol ≤50 mg/dL or Blood Pressure (BP): Systolic BP ≥130 mmHg or Diastolic BP ≥85 mmHg or Hemoglobin A1C ≥ 5.7 and <6.5%

Disqualifiers

Active participation in another research study

Tested positive for COVID-19 within the past 10 days

Been in close contact with a COVID-19 positive person within the past 14 days

Blood Pressure (BP): Systolic BP ≥140 mmHg or Diastolic BP ≥90 mmHg

Trial design

Treatments tested in this trial

  • DGA Mediterranean diet pattern, energy balance
  • DGA Mediterranean diet pattern, negative energy balance
  • TAD diet pattern, negative energy balance

Treatment groups

70 Participants
are divided into 3 treatment groups